Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9311MR)

This product GTTS-WQ9311MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9311MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5811MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CFZ-533
GTTS-WQ5868MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ9469MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ2958MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ14931MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ298MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ4563MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ4443MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-734016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW